Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

in proprietary sales was primarily attributable to increased sales of SEASONIQUE extended cycle oral contraceptive, Plan B Over-the-Counter/Rx and the ParaGard(R) IUC, which more than offset the expected decrease in sales of our SEASONALE extended-cycle oral contraceptive, which has faced generic competition since September 2006, and decreased sales of Adderall(R) IR.

Alliance and Development Revenue

During the first quarter of 2008, the Company reported alliance and development revenue of $32 million, up from $25 million in the prior year period. The increase reflects higher royalties earned from the Company's agreement with Teva Pharmaceuticals on fexofenadine hydrochloride tablets, the generic version of Allegra(R) tablets, and higher reimbursements under its Shire development agreement, which more than offset lower reimbursements under its Adenovirus agreement with the Department of Defense, as the Company completed Phase III clinical trial for Adenovirus during the quarter.

Other Revenue

Other revenue primarily includes revenue from the Company's non-core operations, including the agrochemicals business and the diagnostic, disinfectants, dialysis and infusions (DDD&I) business. Other revenue totaled $11 million for the first quarter of 2008, compared to $12 million in the prior year period.

Margins

Generic: Margins in the generic segment were 50% for the first quarter of 2008, up from 44% in the prior year period. Last year's margins were negatively impacted by a charge of approximately $32 million related to the step-up of inventory acquired from PLIVA and sold in the period.

Proprietary: Margins in the proprietary segment were 68% for the first quarter of 2008, up from 66% in the prior year period.

Update on R&D Activities

Research and development expenses totaled $64 million for the first quarter of 2008, compared to $62 million in the prior year period.

Generic Products

At March 31
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Advanced Pain Remedies (APR), a subsidiary of Cato ... been received, to advance its lead development candidate, SP-SAP. ... of specific cell types to manipulate them for the ... grant from the National Cancer Institute (NCI). Advanced Targeting ...
... Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of ... at the 13th Annual Needham Growth Conference in New York. ... President and COO, and Michael J. Senken, CFO of MiMedx, ... a.m. Eastern Time at the New York Palace Hotel in ...
... 2011 Sutro Biopharma, a biopharmaceutical company developing ... properties, today announced that the company has entered ... research, development and commercialization of novel peptide-based therapeutics. ... Sutro Biopharma will receive an upfront payment of ...
Cached Biology Technology:Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 3Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... They are amongst the most numerous inhabitants of the ... . Not visible to the naked eye, when they ... sized patches, they are even visible on satellite images. ... responsible for approximately half of the global photosynthesis output," ... University Jena (Germany). In the process the greenhouse gas ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2Short circuit in the food web 2
... clue to the causes of autism and mental retardation ... rapidly transfers information from one neuron to the next. ... with students from the Sackler School of Graduate Biomedical ... coli) plays a key role in synapse maturation, and ...
... , CAMBRIDGE, Mass. -- Human pluripotent stem cells, which can ... to treat a wide range of ailments, including Parkinson,s disease, ... with such cells have had trouble growing large enough quantities ... human studies. Furthermore, most materials now used to grow ...
... Mutations in a single gene can cause several ... considered different disorders. With support from the National ... exome sequencing a new gene scanning technology that ... mutations. "This is going to change the way ...
Cached Biology News:Researchers connect APC protein to autism and mental retardation 2MIT researchers develop a better way to grow stem cells 2MIT researchers develop a better way to grow stem cells 3Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3
... temperature-controlled microwave oven for use ... Retrieval of formalin-fixed, paraffin-embedded tissue ... use, high throughput (96 slides ... When used in conjunction with ...
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
Biology Products: